Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bio-Rad Laboratories

242.61
+10.064.33%
Volume:139.31K
Turnover:33.52M
Market Cap:6.60B
PE:-3.15
High:243.75
Open:235.56
Low:234.49
Close:232.55
Loading ...

BRIEF-Bio-Rad Q4 Adjusted EPS USD 2.9 Vs. IBES Estimate USD 2.87

Reuters
·
14 Feb

Bio-Rad Q4 EBIT Margin 8.7%

THOMSON REUTERS
·
14 Feb

Bio-Rad Outlook FY Adjusted Revenue Growth 1.5-3.5%

THOMSON REUTERS
·
14 Feb

Bio-Rad Q4 Sales USD 667.5 Million VS. Ibes Estimate USD 679.3 Million

THOMSON REUTERS
·
14 Feb

Press Release: Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

Dow Jones
·
14 Feb

Bio-Rad Offers to Acquire Digital Pcr Developer Stilla Technologies

THOMSON REUTERS
·
14 Feb

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

Business Wire
·
14 Feb

KALA BIO Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Feb

CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise

Zacks
·
12 Feb

KALA BIO Announces Chief Executive Officer Transition

GlobeNewswire
·
12 Feb

Oncocyte Prices $29 Million Stock Offerings

MT Newswires Live
·
11 Feb

OncoCyte Prices $29.1 Million Equity Offering

THOMSON REUTERS
·
10 Feb

OncoCyte Corp: Proceeds Expected to Fund Transplant Assay Through FDA Ivd Clearance and Commercial Launch

THOMSON REUTERS
·
10 Feb

Oncocyte Prices $29.1 Million Equity Offering

GlobeNewswire
·
10 Feb

Omnicell Q4 Earnings & Revenues Beat, Stock Up, Gross Margin Rises

Zacks
·
10 Feb

Wells Fargo Sticks to Their Hold Rating for Bio-Rad Laboratories (BIO)

TIPRANKS
·
10 Feb

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

GlobeNewswire
·
07 Feb

QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand

Zacks
·
07 Feb

PAHC Stock Falls Despite Q2 Earnings & Revenue Beat, Margins Increase

Zacks
·
07 Feb

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

Zacks
·
06 Feb